Univariate analysis for OS, RFS, and TRM
| Characteristic . | N . | OS . | RFS . | TRM . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | ||
| Age | 176 | 1.02 | 1.00-1.04 | .005 | 1.02 | 1.01-1.04 | .003 | 1.05 | 1.02-1.09 | < .001 |
| Gender | 176 | > .9 | .5 | .7 | ||||||
| Female | — | — | — | — | — | — | ||||
| Male | 1.02 | 0.62-1.66 | 1.15 | 0.73-1.82 | 0.89 | 0.47-1.69 | ||||
| Disease | 176 | > .9 | .5 | > .9 | ||||||
| AML | — | — | — | — | — | — | ||||
| MDS | 0.99 | 0.61-1.60 | 1.17 | 0.75-1.83 | 1.04 | 0.55-1.98 | ||||
| DRI∗ | 172 | .017 | .005 | |||||||
| Low | — | — | — | — | — | — | ||||
| High | 5.30 | 1.22-23.1 | 4.76 | 1.40-16.2 | ||||||
| Intermediate | 2.77 | 0.67-11.4 | 2.18 | 0.68-6.95 | ||||||
| CMV status before HCT | 143 | .11 | .4 | .2 | ||||||
| Negative | — | — | — | — | — | — | ||||
| Positive | 1.52 | 0.90-2.56 | 1.24 | 0.77-1.99 | 1.48 | 0.76-2.87 | ||||
| HCT-CI∗ | 168 | > .9 | .8 | |||||||
| Low | — | — | — | — | — | — | ||||
| High | 1.10 | 0.34-3.60 | 1.35 | 0.42-4.37 | ||||||
| Intermediate | 1.09 | 0.33-3.58 | 1.24 | 0.38-4.04 | ||||||
| Donor | 176 | .038 | .077 | .3 | ||||||
| MRD | — | — | — | — | — | — | ||||
| MMRD/MMURD | 1.96 | 1.00-3.85 | 2.10 | 1.08-4.08 | 1.92 | 0.76-4.86 | ||||
| MURD | 0.88 | 0.49-1.58 | 1.18 | 0.67-2.06 | 1.02 | 0.47-2.25 | ||||
| PopPK cAUC (InsightRX Nova) | 171 | 0.97 | 0.93-1.01 | .085 | 0.98 | 0.94-1.01 | .14 | 0.99 | 0.94-1.03 | .6 |
| PopPK cAUC (InsightRX Nova), binary | 171 | .020 | .020 | |||||||
| <59.5 | — | — | — | — | — | — | .057 | |||
| ≥59.5 | 0.53 | 0.31-0.89 | 0.55 | 0.33-0.89 | 0.50 | 0.26, 0.99 | ||||
| NCA cAUC (WinNonLin, Certara) | 176 | 1.00 | 0.96-1.04 | > .9 | 0.99 | 0.95-1.03 | .7 | |||
| Characteristic . | N . | OS . | RFS . | TRM . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | HR . | 95% CI . | P value . | ||
| Age | 176 | 1.02 | 1.00-1.04 | .005 | 1.02 | 1.01-1.04 | .003 | 1.05 | 1.02-1.09 | < .001 |
| Gender | 176 | > .9 | .5 | .7 | ||||||
| Female | — | — | — | — | — | — | ||||
| Male | 1.02 | 0.62-1.66 | 1.15 | 0.73-1.82 | 0.89 | 0.47-1.69 | ||||
| Disease | 176 | > .9 | .5 | > .9 | ||||||
| AML | — | — | — | — | — | — | ||||
| MDS | 0.99 | 0.61-1.60 | 1.17 | 0.75-1.83 | 1.04 | 0.55-1.98 | ||||
| DRI∗ | 172 | .017 | .005 | |||||||
| Low | — | — | — | — | — | — | ||||
| High | 5.30 | 1.22-23.1 | 4.76 | 1.40-16.2 | ||||||
| Intermediate | 2.77 | 0.67-11.4 | 2.18 | 0.68-6.95 | ||||||
| CMV status before HCT | 143 | .11 | .4 | .2 | ||||||
| Negative | — | — | — | — | — | — | ||||
| Positive | 1.52 | 0.90-2.56 | 1.24 | 0.77-1.99 | 1.48 | 0.76-2.87 | ||||
| HCT-CI∗ | 168 | > .9 | .8 | |||||||
| Low | — | — | — | — | — | — | ||||
| High | 1.10 | 0.34-3.60 | 1.35 | 0.42-4.37 | ||||||
| Intermediate | 1.09 | 0.33-3.58 | 1.24 | 0.38-4.04 | ||||||
| Donor | 176 | .038 | .077 | .3 | ||||||
| MRD | — | — | — | — | — | — | ||||
| MMRD/MMURD | 1.96 | 1.00-3.85 | 2.10 | 1.08-4.08 | 1.92 | 0.76-4.86 | ||||
| MURD | 0.88 | 0.49-1.58 | 1.18 | 0.67-2.06 | 1.02 | 0.47-2.25 | ||||
| PopPK cAUC (InsightRX Nova) | 171 | 0.97 | 0.93-1.01 | .085 | 0.98 | 0.94-1.01 | .14 | 0.99 | 0.94-1.03 | .6 |
| PopPK cAUC (InsightRX Nova), binary | 171 | .020 | .020 | |||||||
| <59.5 | — | — | — | — | — | — | .057 | |||
| ≥59.5 | 0.53 | 0.31-0.89 | 0.55 | 0.33-0.89 | 0.50 | 0.26, 0.99 | ||||
| NCA cAUC (WinNonLin, Certara) | 176 | 1.00 | 0.96-1.04 | > .9 | 0.99 | 0.95-1.03 | .7 | |||
CMV, cytomegalovirus; HCT-CI, HCT comorbidity index; MMRD, mismatched related donor; MMURD, mismatched unrelated donor; MRD, matched related donor; MURD, matched unrelated donor.
The models for HCT-CI and DRI do not converge for the nonrelapse mortality end point.